Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licenses

Bristol Myers Squibb logo

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Group sales rose 6% to $6bn in the third quarter

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combo scores in front-line lung cancer

Makes case for duo therapy in NSCLC patients

- PMLiVE

BMS plugs on with Opdivo plus Yervoy in first-line NSCLC

Could be an alternative treatment option to chemotherapy

- PMLiVE

Third strike for BMS’ Opdivo in brain cancer

Despite failing first endpoint, trial is set to continue

Celgene building

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Currently in the middle of merger

Bristol Myers Squibb logo

Opdivo trial overshadows BMS financial results

Hope remains in Celgene merger

Highlights in haematologic malignancy from ASH 2018

The ASH congress is the most comprehensive haematology event of the year, over 5000 abstracts covering new developments in malignant and non-malignant haematology were presented. Here we focus on two...

Porterhouse Medical Group

- PMLiVE

Regeneron’s early stage bispecific shows promise

Bispecifics and antibody drug conjugates will challenge CAR-Ts

Celgene building

ASH18: CAR-T and drugs give new options for multiple myeloma

San Diego congress showcasing data in important haematology markets

- PMLiVE

More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease

Cell and gene therapy specialist Bluebird going head-to-head with partner Celgene

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to...

Research Partnership

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links